Li made the remarks when visiting the Beijing-based National Institute for the Control of Pharmaceutical and Biological Products, where the country's self-developed vaccines against the A/H1N1 flu are tested.
![]() |
Chinese Vice Premier Li Keqiang (C) gets to know the examining conditions of A/H1N1 flu vaccine during an inspection of the National Institute for the Control of Pharmaceutical and Biological Products in Beijing, capital of China, on Nov. 9, 2009. Li Keqiang inspected here on Monday, which further highlighted the government's resolve to carry on the influenza vaccination campaign amid the growing infections. |
Li noted that autumns and winters were high-occurrence seasons for the flu, and urged the authorities to improve disease prevention and treatment in order to stop the disease from fast spreading across the country.
Authorities should focus on disease prevention in key venues and areas, especially schools, and make active efforts to prevent and deal with mass infection of the disease, Li said.
![]() |
Chinese Vice Premier Li Keqiang (1st R, front) gets to know the production and price of A/H1N1 flu vaccine during an inspection of the National Institute for the Control of Pharmaceutical and Biological Products in Beijing, capital of China, on Nov. 9, 2009. |
Li asked health workers to try their best to keep the disease's death toll from rising and add traditional Chinese medicines into the prevention and treatment of the flu.
As of Monday, the Chinese mainland has reported more than 60,000 cases of the A/H1N1 flu, of which 30 had been fatal. A total of 242 patients were in critical conditions, the Ministry of Health said.
As of Monday, the country has inoculated more than 87 million people with A/H1N1 vaccines. China is the world's first country to issue a production license for the vaccines against the A/H1N1 flu.